Related by context. All words. (Click for frequent words.) 68 EGFR 68 KRAS gene 67 K ras 64 EGFR mutation 64 FLT3 64 KRAS mutations 64 K RAS 63 EGFR mutations 63 KRAS mutation 63 predictive biomarker 62 T#I [002] 62 BCR ABL 61 JAK2 61 HER2 61 K ras gene 60 ERBB2 60 EGFr 59 MicroRNA 59 K ras mutations 59 BRAF mutation 59 microRNAs 59 WT1 59 NPM1 59 HER3 59 KRAS status 59 MGMT gene 58 EGFR tyrosine kinase inhibitors 58 HER2 overexpression 58 CYP#C# [001] 58 JAK3 58 MAPK pathway 58 oncogene 58 Stat5 58 miRNAs 57 Epidermal Growth Factor Receptor 57 VKORC1 57 IGF IR 57 EGFR protein 57 MDM2 57 mCRC patients 57 cyclin D1 57 FGFR1 57 mCRC 57 GNAQ 57 JAK2 V#F 57 Her2 57 EGFR signaling 57 FGFR3 57 CD# [002] 56 LRP6 56 tyrosine kinase 56 IGF 1R 56 BRAF mutations 56 gefitinib Iressa 56 MLH1 56 EGFR inhibitors 56 microRNA expression 56 NSCLC 56 Her2/neu 56 cetuximab 56 Hedgehog pathway 56 Gleevec resistant 56 clusterin 56 STK# [002] 56 PARP inhibitors 56 tumor suppressor protein 56 overexpression 56 Akt 56 PIK3CA 56 factor receptor EGFR 56 CLL cells 56 microRNA 56 Imatinib 56 K ras mutation 56 oncogenic 56 miRNA 56 biomarker 56 cyclin E 55 TAp# 55 B Raf 55 estrogen receptor 55 survivin 55 KRAS mutant 55 HDAC 55 Akt1 55 kinases 55 STAT3 55 ErbB2 positive 55 galectin 3 55 tyrosine kinase inhibitors 55 PTEN gene 55 SOD1 55 Aurora kinase 55 GSTP1 55 tyrosine kinases 55 imatinib Gleevec 55 VEGFR2 55 EGFRvIII 55 metastatic colorectal cancer 55 KRAS wild 55 tumor suppressor gene 55 chronic lymphocytic leukemia CLL 55 NS5A 55 oncogenesis 55 VEGF receptor 55 KRAS oncogene 55 RAR beta 55 GRP# 55 Mcl 1 55 SATB1 55 KRAS mutation status 55 protein kinases 55 colorectal cancer CRC 55 receptor tyrosine kinase inhibitor 55 BRAF gene 55 histone deacetylases 55 HER2 receptor 55 HER1 55 TOP2A 55 breast carcinomas 55 Clusterin 55 DNA methylation 55 TGF β 55 androgen receptor AR 54 mutated K ras 54 nonsmall cell lung cancer 54 Six3 54 mutant KRAS 54 carcinoembryonic antigen 54 NSCLC tumors 54 mutational status 54 miR #a [002] 54 VIPR2 54 molecularly targeted 54 NFkB 54 proto oncogene 54 pancreatic adenocarcinoma 54 somatic mutations 54 E cadherin expression 54 EGFR receptor 54 type KRAS 54 activating mutations 54 tumorigenesis 54 mTOR 54 mitogen activated protein kinase 54 EGF receptor 54 MSH2 54 Flt3 54 epidermal growth 54 metastatic renal cell carcinoma 54 costimulatory 54 decitabine 54 E#F# 54 prognostic markers 54 MammaPrint R 54 Vectibix 54 HER-2/neu 54 PKCi 54 ADAM# 54 HER2 positive 54 N Myc 54 TTR gene 54 NKX#.# 54 p# biomarker 54 hedgehog pathway 54 Smoothened 54 c myc 54 myelofibrosis polycythemia vera 54 Akt activation 54 mutant BRAF 54 CXCR4 54 splice variant 54 HER2/neu 54 kinase 54 epigenetic mechanisms 54 MammaPrint 54 CYP#D# 54 PKM2 54 p# protein 54 mutated KRAS 53 mutant alleles 53 Notch1 53 oncoprotein 53 HER2 neu 53 trastuzumab Herceptin 53 T#I mutation 53 LKB1 53 genes CYP#C# 53 p# Shc 53 T#I mutant 53 vimentin 53 NF kB pathway 53 prognostic marker 53 EphA2 53 OnDose TM 53 TPMT 53 chemosensitivity 53 sorafenib 53 malignant transformation 53 isoform 53 pharmacogenetic 53 castration resistant 53 Fc gamma receptor 53 ErbB3 53 kinase inhibitors 53 NGAL 53 HIF 1alpha 53 NF kB 53 p# MAP kinase 53 caveolin 1 53 CYP#D# genotype 53 PCa 53 IDH1 53 RRM1 53 ZNF# 53 EGFR TKI 53 GISTs 53 Bevacizumab 53 neurofibromin 53 PARP inhibition 53 cancer mCRC 53 Zolinza 53 Bcr Abl 53 LRAT 53 PI3K Akt 53 Src 53 PTPN# 53 cathepsins 53 sunitinib 53 serine threonine kinase 53 predictive biomarkers 53 IDH1 mutation 53 cMET 53 gastrointestinal stromal tumors GISTs 53 human leukocyte antigen 53 Mutational 53 epithelial tumors 53 uPAR 53 CYP#C# [002] 53 DNA methyltransferases 53 qRT PCR 53 Haptoglobin 53 activin 53 LRRK2 53 GBM tumors 53 mRCC 53 kinase inhibition 53 dasatinib Sprycel 53 lymphomas 53 MAGE A3 53 GLI1 53 EZH2 53 c MYC 53 PITX2 53 microRNA miR 53 factor receptor 53 BRAF V#E mutation 53 oncogenes 53 miRNA genes 53 PDGFR 52 HSP# 52 DLC1 52 PTP1B 52 Prox1 52 autoantibody 52 estrogen receptor ER 52 eIF 4E 52 druggable targets 52 EpCAM 52 FOXP3 52 EGFR gene 52 trastuzumab 52 MAPK 52 c MET 52 gene amplification 52 biomarkers 52 sporadic ALS 52 medulloblastomas 52 anti EGFR antibody 52 commonly mutated genes 52 Avastin bevacizumab 52 elacytarabine 52 hTERT 52 prostate cancer CaP 52 methylation patterns 52 Ceflatonin 52 Epratuzumab 52 SPINK1 52 gastrointestinal stromal tumors 52 ERK1 2 52 chemoresistant 52 Torisel 52 telomerase activation 52 Trastuzumab 52 IL#B 52 TNFalpha 52 ErbB2 52 MYCN 52 MAP kinase 52 IFRD1 52 ERCC1 52 CXCR7 52 Diffuse Large B 52 genetic biomarkers 52 Cyclin D1 52 familial ALS 52 immunoregulatory 52 UGT#A# 52 ApoE4 52 p# activation 52 mutant p# 52 lymphocyte 52 miR #a [001] 52 Kinase 52 HER2 positive breast cancer 52 mutated KRAS gene 52 CCR9 52 S#A# [002] 52 enzymatic activity 52 Li Fraumeni 52 Wnt pathway 52 missense mutations 52 microarray analysis 52 homodimer 52 cytogenetic 52 hepatocellular carcinomas 52 castrate resistant 52 colon carcinoma 52 relapsed SCLC 52 biomarker identification 52 beta catenin 52 PROLARIS 52 Janus kinase 52 flavopiridol 52 Foxp3 52 gene expression profiling 52 INGN 52 DNA methylation patterns 52 ALN TTR 52 HBx 52 Methylation 52 prostate tumor 52 small molecule inhibitors 52 Chronic Lymphocytic Leukemia 52 ATTR CM 52 effector function 52 pertuzumab 52 BRAF V#E 52 EGFR expression 52 cell lymphomas 52 leukemic cell 52 Pralatrexate 52 apoptotic pathway 52 siRNA mediated 52 FasL 52 Oncotype 52 cellular pathways 52 molecular profiling 52 epigenetic therapies 52 vemurafenib 52 receptor tyrosine kinase 52 TCF#L# 52 constitutively activated 52 metastatic colorectal 52 IRESSA 52 medullary thyroid cancer 52 LQTS 52 evolutionarily conserved 52 CLL 52 P. falciparum 52 Bcl xL 52 JAK2 enzyme 52 ccRCC 52 prognostic factor 52 CD4 + CD# 52 mTOR inhibitors 52 TERT 51 multiple myeloma MM 51 TP# gene 51 chemoresistance 51 transcription factor 51 XBP1 51 Xanafide 51 activating mutation 51 natriuretic peptide 51 breast cancer metastasis 51 IFN α 51 imatinib therapy 51 CDK8 51 GPx 51 COX2 51 MAPK signaling pathway 51 topoisomerase 51 HSCT 51 glioblastomas 51 imatinib resistant 51 colony stimulating factor 51 MAbs 51 Lyn kinase 51 CYP# [001] 51 p# deficient 51 microarray experiments 51 overexpressed 51 advanced NSCLC 51 Fc receptor 51 Aurora kinases 51 IL 1beta 51 proteasome inhibitors 51 colorectal carcinomas 51 Hedgehog signaling 51 TNFa 51 gastrointestinal stromal tumor GIST 51 KRAS BRAF 51 essential thrombocythemia 51 VeriStrat 51 ß catenin 51 Granulocyte Colony Stimulating Factor 51 tumor progression 51 Squamous 51 LRP5 51 Septin9 51 tyrosine phosphorylation 51 CCX# 51 DHFR 51 nNOS 51 engineered RAP peptides 51 IMA# 51 bevacizumab Avastin 51 P#X# 51 TRAIL induced apoptosis 51 p# MAPK 51 coding sequences 51 standard chemotherapy regimens 51 azacytidine 51 mTOR inhibitor 51 imatinib Gleevec ® 51 TNF α 51 Syk 51 micro RNA 51 protein kinase C 51 serine protease 51 paclitaxel Taxol 51 eIF4E 51 Treg cell 51 IL #R 51 Notch signaling 51 Apoptosis 51 CDK4 51 leukemic stem cells 51 GATA3 51 prognostic biomarker 51 bcl 2 51 metastasis 51 mutant allele 51 companion diagnostics 51 trabectedin 51 miR #b [001] 51 KIT mutations 51 HNSCC 51 HMGCR 51 Raf MEK ERK 51 miRNA expression 51 B CLL 51 BRCA2 51 Revlimid 51 CpG 51 Cdc7 51 GPC3 51 panitumumab 51 enzastaurin 51 transcriptionally 51 Dasatinib 51 p# [001] 51 cilengitide 51 Cytochrome P# 51 HCV protease 51 targeting CD# 51 mAbs 51 BRCA1 51 EGF receptors 51 chronic myeloid leukemia CML 51 thyroglobulin 51 EGFR HER 51 HER2 gene 51 tumor suppressive 51 HGF 51 4E BP1 51 hypoxia inducible factor 51 AGTR1 51 lintuzumab 51 MicroRNAs 51 SOD1 gene 51 VIDAZA 51 promoter methylation 51 HDAC6 51 Nedd4 51 β catenin 51 Mutation Analysis 51 splice variants 51 Phosphorylation 51 V#F mutation 51 erlotinib Tarceva 51 HERmark 51 PCA3 51 EAAT2 51 NPM1 mutation 51 #q# [002] 51 tumor angiogenesis 51 genotypes 51 CDH1 51 EGFR mutation status 51 cetuximab Erbitux 51 IL 7R 51 Mammostrat 51 Irinotecan 51 kinase pathway 51 hypermethylated 51 OGG1 51 dasatinib 51 myeloproliferative neoplasms 51 tumor antigen 51 CellPort Technologies 51 breast carcinoma 51 substrate specificity 51 putative biomarkers 51 leukemia ALL 51 Temsirolimus 51 molecular subtypes 51 Lenalidomide 51 H#K#me# 51 CYC# 51 TrkA 51 gefitinib 51 ubiquitinated 51 STAT1 51 phosphorylation 51 Oncotype DX colon cancer 51 GPR# [001] 51 p# gene 51 JAK2 inhibitors 51 androgen receptor 51 PI3K pathway 51 SNPs 51 TSLP 51 sarcosine 51 Cetuximab 51 tyrosine kinase inhibitor 51 circadian genes 51 metastatic RCC 51 xenograft models 51 BRAF protein 51 fulvestrant 51 protein kinase inhibitor 51 TGF beta pathway 50 epithelial ovarian cancer 50 mutant protein 50 lymph node metastasis 50 CK2 50 bortezomib 50 antibody MAb 50 HER2 positive metastatic breast 50 endoglin 50 Smad3 50 CCL#L# 50 apoptotic 50 Cystatin C 50 tumor suppressor 50 pDCs 50 protein kinase 50 Aplidin 50 ApoE 50 castration resistant prostate cancer 50 immunostaining 50 protein p# 50 imatinib resistance 50 virulence genes 50 cytokine 50 molecular biomarkers 50 uPA 50 response pCR 50 BRCA1 BRCA2 50 glioblastoma cells 50 Rituximab 50 PARP inhibitor 50 FLT3 mutations 50 methylated DNA 50 lactate dehydrogenase LDH 50 androgen independent 50 lymphoid 50 TLR9 agonists 50 XYOTAX TM 50 DEAR1 50 KLF4 50 tumorigenic 50 Erlotinib 50 poly ADP ribose polymerase 50 RANK ligand 50 BiTE 50 Amrubicin 50 C EBP alpha 50 mutant SOD1 50 B7 H3 50 ERK pathway 50 seliciclib 50 Velcade bortezomib 50 diagnostic biomarker 50 nestin 50 alternatively spliced 50 KIAA# 50 B lymphocyte 50 B lymphocytes 50 recombinant erythropoietin 50 PHD2 50 IFN gamma 50 immunohistochemistry 50 mAb 50 Follicular Lymphoma 50 genomic 50 trastuzumab Herceptin ® 50 Lp PLA2 50 colorectal carcinoma 50 ras oncogene 50 OncoVEX GM CSF 50 pegylated interferon alpha 50 NKG2D 50 protein Mcl 1 50 caspase 50 Leukemias 50 glycogen synthase kinase 50 TSP1 50 homeobox gene 50 PC3 cells 50 carcinoid 50 NF kappaB 50 pharmacodynamic biomarkers 50 genomic alterations 50 Wnt signaling pathway 50 cytokeratin 50 medulloblastoma 50 EGFR pathway 50 malignant pleural mesothelioma 50 transcription factors 50 CTGF 50 histone deacetylase HDAC inhibitor 50 FDG PET 50 mediated apoptosis 50 diabetic nephropathy 50 Herceptin trastuzumab 50 CYP# [002] 50 Azacitidine 50 CD# mAb 50 ncRNAs 50 chemokine receptor 50 hypermethylation 50 p# tumor suppressor 50 oncoproteins 50 glycosylated 50 TLR3 50 Id1 50 ALK inhibitors 50 PLX# 50 induces apoptosis 50 HRPC 50 Rap1 50 myeloid 50 squamous cell lung cancer 50 distant metastasis 50 BCL6 50 Taxotere ® 50 XmAb# 50 FOLFOX chemotherapy 50 LHRH 50 proteolytic cleavage 50 lupus nephritis 50 IRF6 50 interferon IFN 50 microsatellite instability 50 microRNA molecules 50 MGUS 50 molecular markers 50 c Myb 50 mutational analysis 50 adipogenic 50 Vidofludimus 50 Acute Myeloid Leukemia 50 AMACR 50 PI3K 50 PI3 kinase 50 thymalfasin 50 FGFR 50 endostatin 50 HDAC inhibition 50 Bcl 2 50 myeloproliferative diseases 50 Huntingtin 50 Tumor Necrosis Factor 50 peroxisome proliferator activated 50 pro angiogenic 50 mutation 50 indolent lymphomas 50 Wwox 50 SIRT2 50 mRNAs 50 coding genes 50 isotypes 50 immunoglobulin genes 50 myeloma cells 50 Stat3 50 anaplastic lymphoma kinase 50 sDNA 50 Theranostics 50 histologies 50 BRAF inhibitor 50 platelet reactivity 50 NMP# 50 ERK signaling 50 mRNA expression 50 gastric carcinogenesis 50 pCR 50 bone metastasis 50 IL 1β 50 FGFR2 50 FLT3 ITD 50 neurite outgrowth 50 TRAF1 C5 50 E cadherin 50 FOLFIRI 50 CDKs 50 telomerase reverse transcriptase 50 microdeletions 50 CDK inhibitor 50 transcriptional repressor 50 mutated p# 50 EphB4 50 Symadex 50 annexin V 50 Bortezomib 50 tubulin inhibitor 50 thalidomide Thalomid 50 Novartis Gleevec 50 Interferon alfa 50 PITX2 methylation 50 synuclein 50 Her-2/neu 50 histone modifications 50 TGF b 50 phospho 50 FUS1 50 major histocompatibility complex 50 ABCB1 50 chromosomal rearrangement 50 glucocorticoid receptor 50 CagA 50 BRCA genes 50 sorafenib Nexavar 50 causal variants 50 EGFR mutant 50 noncoding RNAs 50 situ hybridization 50 NFκB 50 chromosomal aberrations 50 interferon alfa 50 lysosomal 50 breast cancer subtypes 50 interferon 50 Pten 50 metastatic renal cell 50 effector functions 50 cAMP signaling 50 cytogenic 50 mTOR signaling 50 Omnitarg 50 Reovirus 50 MMP9 50 alpha synuclein 50 methyltransferases 50 preclinically 50 pro apoptotic 50 situ LCIS 50 p#NTR 50 melanocortin receptors 50 OCT4 50 anti angiogenic agents 50 azacitidine 50 GPCRs 50 regulating gene expression 50 prognostic indicator 50 ARF1 50 Oct4 50 CHD5 50 rhIGFBP 3 50 chemokines 50 ubiquitination 50 miR #b [002] 50 hypereosinophilic syndrome 50 erlotinib Tarceva ® 50 rs# [002] 50 bucindolol 50 antiproliferative effects 50 apoE 50 AAV2 50 HIF 1a 50 protein tyrosine phosphatase 1B 50 BCL#A 50 leukemic cells 50 HER2 expression 50 antisense oligonucleotide 50 secretory phospholipase A2 sPLA2 50 PPAR γ 50 CD# antibody [001] 50 melatonin receptor 50 anti inflammatory cytokine 50 genotypic 50 HDACs 50 ovarian carcinoma 50 adenocarcinomas 50 EGFR mutation positive 50 prostate carcinoma 50 mesothelin 50 metastatic melanoma 50 transmembrane protein 50 mutations 50 NPM1 mutations 50 cyclin dependent kinases 50 overexpressing cells 50 MnSOD 49 secretory pathway 49 liver metastasis 49 protein isoforms 49 temsirolimus 49 EGFR HER2 49 genotype 49 transgenic mouse model 49 SUTENT 49 missense mutation 49 regorafenib 49 antisense inhibition 49 ON #.Na 49 monocyte 49 mapatumumab 49 IgG antibodies 49 antiapoptotic 49 RBP4 49 IKZF1 49 mTOR pathway 49 Jhdm2a 49 MUC1 49 MTHFR gene 49 ALDH 49 Th# 49 Nilotinib 49 Septin 9 49 Vidaza R 49 single nucleotide polymorphism 49 RKIP 49 ErbB 49 mammary cells 49 genetic polymorphism 49 cisplatin resistant 49 transgene expression 49 Smurf1 49 neuroendocrine tumors 49 small RNAs 49 antiangiogenic therapy 49 mTOR mammalian target 49 AlloMap 49 hepatocellular carcinoma 49 erlotinib 49 metabolic enzymes 49 XIAP 49 plasma kallikrein 49 CD#L 49 CTLA 4 49 antisense oligonucleotides 49 MIF protein 49 ubiquitin ligases 49 dasatinib Sprycel ® 49 DLBCL 49 histone deacetylase inhibitors 49 anaplastic lymphoma kinase ALK 49 CD# + [002] 49 GSK3 49 ghrelin receptor 49 etoposide 49 CYP#D# gene 49 NF1 49 urothelial carcinoma 49 MLL2 49 E3 ubiquitin ligase 49 glioma cells 49 HIF 1α 49 pomalidomide 49 EML4 ALK 49 Wnt signaling 49 indolent NHL 49 antibody mediated 49 miRview ™ squamous 49 ADPKD 49 hepatocyte 49 Cutaneous T 49 Epigenomics proprietary 49 Prognostic 49 ependymoma 49 CFTR gene 49 SGK1 49 ependymomas 49 thymocytes 49 IFN γ 49 CYT# potent vascular disrupting 49 urine cytology 49 HAAH 49 p# mutations 49 HGS ETR2 49 Recurrence Score 49 NT proBNP 49 Mdm2 49 chronic myelogenous leukemia CML 49 ptau 49 prostate specific 49 M#V mutation 49 FOXO3a 49 hypomethylating agents 49 myeloproliferative disorders 49 SLC#A# [002] 49 Hsp# [002] 49 MAb 49 protein encoded 49 Galectin 49 HOTAIR 49 methylation 49 oxysterols 49 histologic 49 PSMA ADC 49 primary cilia 49 bendamustine 49 #p# [001] 49 transcriptional activation 49 alternative splicing 49 methylation markers 49 hormone refractory 49 Fludarabine 49 ALK mutations 49 miRview TM mets 49 olaparib 49 Myc 49 immunoreactivity 49 anti JCV antibodies 49 proapoptotic 49 LRRK2 gene 49 MALT lymphoma 49 Kinases 49 Eg5 49 HGS ETR1 49 intron 49 LHRH receptor 49 depsipeptide 49 gastric carcinoma 49 induce apoptosis 49 pancreatic islet 49 estrogen receptor alpha 49 CCR3 49 myeloid cells 49 cell signaling pathway 49 K#N 49 serotonin receptor 49 genetic polymorphisms 49 bladder carcinoma 49 micro RNAs 49 estrogen receptor progesterone receptor 49 serologic 49 Decitabine 49 PALB2 49 adjuvant chemotherapy 49 chemokine 49 Azedra 49 LungExpress Dx TM 49 Tyrosine Kinase Inhibitor 49 cis regulatory 49 isoforms 49 YONDELIS 49 standard chemotherapy regimen 49 estrogen receptor beta 49 FKBP# 49 lymphoid cells 49 histone acetylation 49 IRF5 49 haematopoietic 49 Sox2 49 breast cancers 49 Interleukin 49 Caspase 49 PSP# [002] 49 SMN2 49 ubiquitylation 49 #q#.# [001] 49 tyrosine kinase receptor 49 K#R [002] 49 UTRs 49 RT qPCR